Change and Innovation
BioPharm International is the longest-running peer-reviewed publication dedicated to your work.
Recently we announced the appointment of Michelle Hoffman as Editorial Director of Advanstar's Pharmaceutical Drug Development and Manufacturing Group, which now includes BioPharm International, Pharmaceutical Technology, Pharmaceutical Technology Europe, and the IVT Journals. I am pleased to join Ms. Hoffman as BioPharm International's new publisher.
Allen Basis
It is exciting to work with an editor whose curriculum vita matches our tagline, "The Science & Business of Pharmaceuticals." Michelle's appointment and my employment and dedication to BioPharm International are examples of an evolving list of investments Advanstar Communications, our parent, is making in the brand. With more than 20 years of media management, I am dedicated to developing new and innovative ways of delivering the content you've come to depend on in print and online.
BioPharm International is the longest-running peer-reviewed publication dedicated to facilitating your work in the development and manufacturing of biotherapeutics and managing related business issues. Our goal is to provide the most up-to-date, reliable, and insightful information available to you in the biopharmaceutical market. To ensure that we meet your needs, I will seek your opinions about our performance.
We strive to equip you to manage your technical and business challenges effectively, but if we can serve you better with more news and information on tools, techniques, or business, we invite you to please let us know. Please drop us a line and be sure to look for us at industry conferences and expos throughout the year.
All the best,
Allen Basis is the publisher of BioPharm International, abasis@advanstar.com.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
